Cost-effectiveness of rosuvastatin in comparison with generic atorvastatin and simvastatin in a Swedish population at high risk of cardiovascular events.

ClinicoEconomics and Outcomes Research : CEOR
Sanjay GandhiThomas Paulsson

Abstract

To assess the long-term cost-effectiveness of rosuvastatin therapy compared with generic simvastatin and generic atorvastatin in reducing the incidence of cardiovascular events and mortality in a Swedish population with Framingham risk ≥20%. A PROBABILISTIC MONTE CARLO SIMULATION MODEL BASED ON DATA FROM JUPITER (THE JUSTIFICATION FOR THE USE OF STATINS IN PREVENTION: an Intervention Trial Evaluating Rosuvastatin) was used to estimate the long-term cost-effectiveness of rosuvastatin 20 mg daily versus simvastatin or atorvastatin 40 mg for the prevention of cardiovascular death and morbidity. The three- stage model included cardiovascular event prevention simulating the 4 years of JUPITER, initial prevention beyond the trial, and subsequent cardiovascular event prevention. A Swedish health care payer perspective (direct costs only) was modeled for a lifetime horizon, with 2008/2009 as the costing period. Univariate and probabilistic sensitivity analyses were performed. The incremental cost per quality-adjusted life-year (QALY) gained with rosuvastatin 20 mg over simvastatin or atorvastatin 40 mg ranged from SEK88,113 (rosuvastatin 20 mg versus simvastatin 40 mg; Framingham risk ≥30%; net avoidance of 34 events/1000 patients) to ...Continue Reading

References

Jan 1, 1991·American Heart Journal·K M AndersonW B Kannel
May 26, 1998·JAMA : the Journal of the American Medical Association·J AvornJ LeLorier
Feb 1, 2003·PharmacoEconomics·Tammy O Tengs, Ting H Lin
Jun 6, 2003·European Heart Journal·R M ConroyUNKNOWN SCORE project group
Sep 11, 2003·European Heart Journal·Guy De BackerUNKNOWN Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice
Sep 16, 2004·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Hans-Georg EichlerBengt Jönsson
Sep 28, 2004·International Journal of Technology Assessment in Health Care·Ola GhatnekarAndreas Terént
Jan 28, 2005·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Ya-Chen Tina ShihScott B Cantor
Jun 17, 2006·Cardiovascular Drugs and Therapy·Paul A Scuffham, József Kósa
Sep 1, 2006·The New England Journal of Medicine·David M CutlerSandeep Vijan
Oct 12, 2007·The New England Journal of Medicine·Ian FordUNKNOWN West of Scotland Coronary Prevention Study Group
Jun 20, 2008·PharmacoEconomics·Martin Hoyle
Nov 11, 2008·The New England Journal of Medicine·Paul M RidkerUNKNOWN JUPITER Study Group
Mar 31, 2009·The New England Journal of Medicine·Robert J GlynnPaul M Ridker
Dec 25, 2009·Circulation. Cardiovascular Quality and Outcomes·Rickard CarlhedUNKNOWN Quality Improvement in Coronary Care Study Group

❮ Previous
Next ❯

Citations

Dec 18, 2012·Cardiovascular Drugs and Therapy·Steven Simoens, Peter R Sinnaeve
Feb 20, 2014·Indian Journal of Pharmacology·Abdulbari BenerAbdulla O A A Al-Hamaq
Nov 18, 2017·Expert Review of Pharmacoeconomics & Outcomes Research·Dong-Churl SuhTaehwan Park
Nov 2, 2013·Expert Review of Pharmacoeconomics & Outcomes Research·Donald W SmithKaren Chung
Jul 13, 2021·International Journal of Preventive Medicine·Mahmoud EisaviAbdosaleh Jafari
Sep 30, 2021·Cardiology and Therapy·Konstantinos TsioufisJoris van Vugt

❮ Previous
Next ❯

Software Mentioned

JUPITER

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.